Skip to main content
SpringerLink
Log in

Topoisomerases in Multidrug Resistance

  • Chapter
Alternative Mechanisms of Multidrug Resistance in Cancer

  • 40 Accesses

Abstract

Multidrug resistance (MDR) in cancer refers to the phenomenon whereby the treatment with one chemotherapeutic drug induces pleiotropic resistance toward drugs that are unrelated to the original compound. Since the acquisition of MDR in cancer is one of the obstacles in the management of cancer, the elucidation of the MDR mechanisms and the development of therapeutics to overcome clinical MDR are major concerns in cancer chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Allsopp TE, Wyatt S, Paterson HF, Davies AM (1993): The proto-oncogene bcl-2 can selectively rescue neurotrophic factor-dependent neurons from apoptosis. Cell 73:295–307

    Article  PubMed  CAS  Google Scholar 

  • Alt FW, Kellems RE, Bertino JR, Schimke RT (1978): Selective multiplication of dihydrofolate in methotrexate-resistant variants of cultured murine cells. J Biol Chem 253:1357–1370

    PubMed  CAS  Google Scholar 

  • Andersson HC, Kihlman BA (1989): The production of chromosomal alterations in human lymphocytes by drugs known to interfere with the activity of DNA topoisomerase II. I. m-AMSA. Carcinogenesis 10:123–130

    Article  PubMed  CAS  Google Scholar 

  • Andoh T, Ishii K, Suzuki Y, Ikegami Y, Kusunoki Y, Takemoto Y, Okada K (1987): Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84:5565–5569

    Article  PubMed  CAS  Google Scholar 

  • Austin CA, Fisher LH (1990): Isolation and characterization of a human cDNA clone encoding a novel DNA topoisomerase II homologue from HeLa cells. FABS Lett 266:115–117

    Article  CAS  Google Scholar 

  • Austin CA, Sng JH, Petel S, Fisher LM (1993): Novel HeLa topoisomerase II is the Il-beta isoform: Complete coding sequence and homology with other type II topoisomerases. Biochim Biophys Acta 1172:283–291

    PubMed  CAS  Google Scholar 

  • Beck WT, Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton JS, Suttle DP, Trent JM (1987): Pharmacological, molecular, and cytogenetic analysis of “atypical” multidrug-resistant human leukemic cells. Cancer Res 47:5455–5460

    PubMed  CAS  Google Scholar 

  • Bertrand R, O’Connor PM, Kerrigan D, Pommier Y (1992): Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer 28A:743–748

    Article  PubMed  CAS  Google Scholar 

  • Bjornsti M-A, Benedetti P, Viglianti GA, Wang JC (1989): Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: Restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res 49:6318–6323

    PubMed  CAS  Google Scholar 

  • Bojanowski K, Lelievre S, Markovits J, Couprie J, Jacquemin-Sablon A, Larsen AK (1992): Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Proc Nalt Acad Sci USA 89:3025–3029

    Article  CAS  Google Scholar 

  • Bugg BY, Danks MK, Beck WT, Suttle DP (1991): Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemia cells selected for resistance to teniposide. Proc Nalt Acad Sci USA 88:7654–7658

    Article  CAS  Google Scholar 

  • Cardenas ME, Dang Q, Glover CVC, Gasser SM (1992): Casein kinase II phosphorylates the eukaryote-specific C-terminal domain of topoisomerase II in vivo. EMBO J 11:1785–1796

    PubMed  CAS  Google Scholar 

  • Chan VT-W, Ng S, Eder JP, Schnipper LE (1993): Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line. J Biol Chem 268:2160–2165

    PubMed  CAS  Google Scholar 

  • Chen AY, Yu C, Potmesil M, Wall ME, Wani MC, Liu LF (1991): Camptothecin overcomes MDR 1-mediated resistance in human KB carcinoma cells. Cancer Res 51:6039–6044

    PubMed  CAS  Google Scholar 

  • Chen AY, Yu C, Bodley A, Peng LF, Liu LF (1993): A new mammalian DNA topoisomerase I poison Hoechst 33342: Cytotoxicity and drug resistance in human cell cultures. Cancer Res 53:1332–1337

    PubMed  CAS  Google Scholar 

  • Chow K-C, Ross WE (1987): Topoisomerase II-specific drug sensitivity in relation to cell cycle progression. Mol Cell Biol 7:3119–3123

    PubMed  CAS  Google Scholar 

  • Chung TDY, Drake FH, Tan KB, Per SR, Crooke ST, Mirabelli CK (1989): Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acd Sci USA 86:9431–9435

    Article  CAS  Google Scholar 

  • Corbett AH, Osheroff N (1993): When good enzymes go bad: Conversion of topoisomerase II to a cellular toxin by antitumor drugs. Chem Res Toxicol 6:585–597

    Article  PubMed  CAS  Google Scholar 

  • Danks MK, Yalowich JC, Beck WT (1987): Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res 47:1297–1301

    PubMed  CAS  Google Scholar 

  • Danks MK, Schmidt CA, Cirtain MC, Suttle DP, Beck WT (1988): Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemia cells selected for resistance to VM26. Biochemistry 27:8861–8869

    Article  PubMed  CAS  Google Scholar 

  • Danks MK, Warmouth MR, Friche E, Granzen B, Bugg BY, Harker WG, Zwelling LA, Futscher BW, Suttle DP, Beck WT (1993): Single-strand conformational polymorphism analysis of the Mr 170.000 isozyme of DNA topoisomerase II in human tumor cells. Cancer Res 53:1373–1379

    PubMed  CAS  Google Scholar 

  • Davies SM, Robson CN, Davies SL, Hickson ID (1988): Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Chem 263:17724–17729

    PubMed  CAS  Google Scholar 

  • Deffie AM, Batra JK, Goldenberg G J (1989): Direct correlation between DNA topoisomerase II activity and cytotoxicity in Adriamycin-sensitive and — resistant P388 leukemia cell lines. Cancer Res 49:58–62

    PubMed  CAS  Google Scholar 

  • DeVore RF, Corbett AH, Osheroff N (1992): Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: Effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4′-(9-acridinylamino)-methane-sulfon-m-aniside. Cancer Res 52:2156–2161

    PubMed  CAS  Google Scholar 

  • Drake FH, Zimmerman JP, McCabe FL, Bartus HF, Per SR, Sullivan DM, Ross WE, Mattem MR, Johnson RK, Crooke ST, Mirabelli CK (1987): Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells: Evidence for two forms of the enzyme. J Biol Chem 262:16139–16147

    Google Scholar 

  • Drake FH, Hofman GA, Bartus HF, Mattem MR, Crooke ST, Mirabelli CK (1989): Biochemical and pharmacological properties of pl70 and pl80 forms of topoisomerase II. Biochemistry 28:8154–8160

    Article  PubMed  CAS  Google Scholar 

  • Elsea SH, McGuirk PR, Gootz TD, Moynihan M, Osheroff N (1993): Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: Correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential. Antimicrob Agents Chemother 37:2179–2186

    PubMed  CAS  Google Scholar 

  • Eng WK, McCabe FL, Tan KB, Mattem MR, Hofmann GA, Woessner RD, Hertzberg RP, Johnson RK (1990): Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol 38:471–480

    PubMed  CAS  Google Scholar 

  • Fan D, Beltran PJ, OBrian CA (1994): Reversal of multidrug resistance. In: Reversal of Multidrug Resistance in Cancer, (ed. JA Kellen), pp. 93–125. Boca Raton: CRC Press

    Google Scholar 

  • Feldhoff PW, Mirski SEL, Cole SPC, Sullivan DM (1994): Altered subcellular distribution of topoisomerase IIα in a drug-resistant human small cell lung cancer cell line. Cancer Res 54:756–762

    PubMed  CAS  Google Scholar 

  • Fisher TC, Milner AE, Gregory CD, Jackman AL, Aherne GW, Hartley JA, Dive C, Hickman JA (1993): bcl-2 modulation of apoptosis induced by anticancer drugs: Resistance to thymidylate stress is independent to classical resistance pathways. Cancer Res 53:3321–3326

    PubMed  CAS  Google Scholar 

  • Fosse P, Paoletti C, Saucier J-M (1988): Pattern of recognition of DNA by mammalian DNA topoisomerase II. Biochem Biophys Res Commun 151:1233–1240

    Article  PubMed  CAS  Google Scholar 

  • Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Masters JRW, Hichson ID (1991): Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 51:6592–6595

    PubMed  CAS  Google Scholar 

  • Furue H (1994): Irinotecan hydrochloride (CPT-11). Jpn J Cancer Chemother 21:709–717

    CAS  Google Scholar 

  • Garcia I, Martinou I, Tsujimoto Y, Martinou J-C (1992): Prevention of programmed cell death of sympathetic neurons by the bcl-2 proto-oncogene. Science 258:302–304

    Article  PubMed  CAS  Google Scholar 

  • Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M (1989): DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246:1046–1048

    Article  PubMed  CAS  Google Scholar 

  • Glisson B, Gupta R, Hodges P, Ross W (1986): Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: Evidence for a common intracellular target. Cancer Res 46:1939–1942

    PubMed  CAS  Google Scholar 

  • Han Y-H, Austin MJF, Pommier Y, Povirk LF (1993): Small deletion and insertion mutations induced by the topoisomerase II inhibitor teniposide in CHO cells and comparison with sites of drug-stimulated DNA cleavage in vitro. J Mol Biol 229:52–66

    Article  PubMed  CAS  Google Scholar 

  • Harker WG, Slade DL, Holguin MH, Feldhoff PW, Sullivan DM (1994): Mitoxantrone-resistant HL-60 leukemia cells contain an altered topoisomerase II alpha gene, mRNA and subcellular protein distribution. Proc Am Assoc Cancer Res 35:2707

    Google Scholar 

  • Hashimoto S, Chatterjee S, Danks KM, Beck WT (1994): Point mutation in the vicinity of the DNA binding domain of topoisomerase II gene is associated with the development of resistance to VP-16. Proc Am Assoc Cancer Res 35:2720

    Google Scholar 

  • Hech MMS, Hittelman WN, Eamshaw WC (1989): In vivo phosphorylation of the 170-kDa form of eukaryotic DNA topoisomerase II: Cell cycle analysis. J Biol Chem 264:15161–15164

    Google Scholar 

  • Heck MMS, Eamshaw (1986): Topoisomerase II: Specific marker for cell proliferation. J Cell Biol 103:2569–2581

    Article  PubMed  CAS  Google Scholar 

  • Hickman JA (1992): Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 11:121–139

    Article  PubMed  CAS  Google Scholar 

  • Hinds M, Disseroth K, Mayes J, Altschuler E, Jansen R, Ledley FD, Zwelling LA (1991): Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res 51:4729–4731

    PubMed  CAS  Google Scholar 

  • Hirabayashi N, Kim R, Nishiyama M, Aogi K, Saeki S, Toge T, Okada K (1992): Tissue expression of topoisomerase I and II in digestive tract cancers and adjacent normal tissues. Pro Am Assoc Cancer Res 33:2603

    Google Scholar 

  • Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ (1990): Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334–336

    Article  PubMed  CAS  Google Scholar 

  • Holden JA, Rolfson DH, Wittwer CT (1990): Human DNA topoisomerase II: Evaluation of enzyme activity in normal and neoplastic tissues. Biochemistry 29:2127–2134

    Article  PubMed  CAS  Google Scholar 

  • Holden JA, Rolfson DH, Wittwer CT (1992): The distribution of immunoreactive topoisomerase II protein in human tissue and neoplasms. Oncol Res 4:157–166

    PubMed  CAS  Google Scholar 

  • Hsiang Y-H, Hertzberg R, Hecht S, Liu LF (1985): Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873–14878

    PubMed  CAS  Google Scholar 

  • Hsiang Y-H, Jiang JB, Liu LF (1989): Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs. Mol Pharmacol 36:371–376

    PubMed  CAS  Google Scholar 

  • Husain I, Mohler JL, Seigier HF, Besterman JM (1994): Elevation of topoisomerase messenger RNA, protein, and catalytic activity in human tumor: Demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 54:539–546

    PubMed  CAS  Google Scholar 

  • Jenkins JR, Ayton P, Jones T, Davies SL, Simmons DL, Harris AL, Sheer D, Hickson ID (1992): Isolation of cDNA clones encoding the β isozyme of human DNA topoisomerase II and localization of the gene to chromosome 3p24. Nucleic Acids Res 20:5587–5592

    Article  PubMed  CAS  Google Scholar 

  • Johnson RK, McCabe FL, Faucette LF, Hertzberg RP, Kingsbury WD, Boehm JC, Caranfa MJ, Holden KG (1989): SK&F10864, a water-soluble analog of camptothecin with broad-spectrum activity in preclinical tumor models. Proc Am Assoc Cancer Res 30:623

    Google Scholar 

  • Kamath N, Grabowski D, Ford J, Kerrigan D, Pommier Y, Ganapathi R (1992): Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone. Biochem Pharmacol 44:937–945

    Article  PubMed  CAS  Google Scholar 

  • Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y, Cossman J (1993): bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 53:4251–4256

    PubMed  CAS  Google Scholar 

  • Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K, Fujiwara Y, Liu LF, Saijo N (1990): Establishment of a camptothecin analogue (CPT-1l)-resistant cell line of human non-small cell lung cancer: Characterization and mechanism of resistance. Cancer Res 50:5919–5924

    PubMed  CAS  Google Scholar 

  • Kaufmann SH (1991): Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51:1129–1136

    PubMed  CAS  Google Scholar 

  • Kim R, Hirabayashi N, Nishiyama M, Jinushi K, Toge T, Okada K (1992): Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer 50:760–766

    Article  PubMed  CAS  Google Scholar 

  • Kimura K, Yamada K, Yoshida T (1986): Phase II study of NK171 (etoposide) on malignant lymphomas and acute leukemia. Jpn J Cancer Chemother 13:496–501

    CAS  Google Scholar 

  • Konno K, Nagahama F, Nakai Y, Nakabayashi T, Hiraga Y, Takebe K, Tamura M, Oizumi K, Sato M, Ito T, Hayashi I (1986): A phase II study of intravenous VP-16-213 in small cell and non-small cell carcinoma of the lung. Jpn J Cancer Chemother 13:931–937

    CAS  Google Scholar 

  • Kunikane H, Ohta S, Kubota N, Takeda Y, Nishino K, Saijo N, Krisham A (1990): Relationship between amount of P-glycoprotein and cellular adriamycin retention in lung cancer cell lines. Proc Am Assoc Cancer Res 34:1836

    Google Scholar 

  • Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M (1987): Antitumor activity of 7-Ethyl-10-[4-(l-piperidino)-l-piperidino]carbonyloxy-c amptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47:5944–5947

    PubMed  CAS  Google Scholar 

  • Larsen AK, Grondard L, Couprie J, Desoize B, Comoe L, Jardillier J-C, Riou J-F. (1993): The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerase I and II. Biochem Pharmcol 46:1403–1412

    Article  CAS  Google Scholar 

  • Lee M-S, Wang JC, Beran M (1992): Two independent amsacrine-resistant leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II. J Mol Biol 223:837–843

    Article  PubMed  CAS  Google Scholar 

  • Liu LF, Miller KG (1981): Eukaryotic DNA topoisomerases: Two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc Natl Acad Sci USA 78:3487–3491

    Article  PubMed  CAS  Google Scholar 

  • Liu LF (1989): DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58:351–375

    Article  PubMed  CAS  Google Scholar 

  • Liu LF (1990): Anticancer drugs that convert DNA topoisomerases into DNA damaging agents. In: DNA Topology and Its Biological Effects, (ed. NR Cozzarelli and JC Wang), pp. 371–389. Cold Spring Harbor: Cold Spring Harbor Laboratory Press

    Google Scholar 

  • Lonn U, Lonn S, Nylen U, Winbald G (1989): Altered formation of DNA in human cells treated with inhibitors of DNA topoisomerase II (etoposide and teniposide). Cancer Res 49:6202–6207

    PubMed  CAS  Google Scholar 

  • Lynn R, Giaever G, Swanberg SL, Wang JC (1986): Tandem regions of yeast DNA topoisomerase II share homology with different subunits of bacterial gyrase. Science 233:647–649

    Article  PubMed  CAS  Google Scholar 

  • Madden KR, Champoux JJ (1992): Overexpression of human topoisomerase I in baby hamster kidney cells: Hypersensitivity of clonal isolates to camptothecin. Cancer Res 52:525–532

    PubMed  CAS  Google Scholar 

  • Matsuo K, Kohno K, Takano H, Sato S, Kiue A, Kuwano M (1990): Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines. Cancer Res 50:5819–5824

    PubMed  CAS  Google Scholar 

  • Miyashita T, Reed JC (1992): bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52:5407–5411

    PubMed  CAS  Google Scholar 

  • Miyashita T, Reed JC (1993): Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151–157

    PubMed  CAS  Google Scholar 

  • Muriaux D, Lavelle F, Riou JF (1993): Establishment of murine cell lines resistant to the topoisomerase I and II inhibitor intoplicine. Proc Am Assoc Cancer Res 34:2542

    Google Scholar 

  • Negoro S, Fukuoka M, Niitani H, Suzuki A, Nakabayashi T, Kimura M, Motomiya M, Kurita Y, Hasegawa K, Kuriyama T, Nishiwaki Y, Ogawa M, Nakao I, Saijyo N, Obo K, Furue H, Aryiyoshi Y, Shimokawa K, Furuse K, Nakajima S, Irie K, Kimura I, Ogura T, Fujii M, Hara N, Hara Y, Nakano S, Araki J, Miyata Y, Taguchi T (1991): A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. Jpn J Cancer Chemother 18:1013–1019

    CAS  Google Scholar 

  • Nelson EM, Tewey KM, Liu LF (1984): Mechanism of antitumor drug action: Poisoning of mammalian DNA topoisomerase II by 4′-(9-acridinylamino)methanesulfon-m-anisidide. Proc Nalt Acad Sci USA 81:1361–1365

    Article  CAS  Google Scholar 

  • Nergi C, Chiesa R, Cerino A, Bestagno M, Sala C, Zini N, Naraldi AM, Ricotti GCBA (1992): Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170- and 180-kDa isozymes. Exp Cell Res 200:452–459

    Article  Google Scholar 

  • Nunez G, London L, Hockenbery D, Alexander M, McKeam JP, Korsmeyer SJ (1990): Deregulated bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 144:3602–3610

    PubMed  CAS  Google Scholar 

  • Ogawa M, Kurita S, Nishimura J, Kamei Y, Ariyoshi Y, Murakami M, Oyama A, Sugiura T, Kato R, Ohta K, Nakamura A (1972): Clinical trial with adriamycin, a new antibiotic, in treatment of malignant neoplasms. Jpn J Cancer Clin 18:806–812

    Google Scholar 

  • Ogawa M, Taguchi T (1992): Clinical studies with CPT-11: The Japanese experience. Ann Oncol 3:118

    Google Scholar 

  • Ohmori T, Podack ER, Nishio K, Takahashi M, Miyahara Y, Takeda Y, Kubota N, Funayama Y, Ogasawara H, Ohira T, Saijo N (1993): Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADR) is inhibited by bcl-2. Biochem Biophys Res Commun 15:30–36

    Article  Google Scholar 

  • Onishi Y, Azuma Y, Sato Y, Mizuno Y, Tadakuma T, Kizaki H (1993): Topoisomerase inhibitors induce apoptosis in thymocytes. Biochim Biophys Acta 1175:147–154

    Article  PubMed  CAS  Google Scholar 

  • Osheroff N (1989): Biochemical basis for the interactions of type I and type II topoisomerases with DNA. Pharmacol Ther 41:223–241

    Article  PubMed  CAS  Google Scholar 

  • Patel S, Fisher LM (1993): Novel skeleton and genetic characterization of an etoposide-resistant human leukemic CCRF-CEM cell line. Br J Cancer 67:456–463

    Article  PubMed  CAS  Google Scholar 

  • Poddevin B, Riou J-F, Lavelle F, Pommier Y (1993): Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. Mol Pharmacol 44:767–774

    PubMed  CAS  Google Scholar 

  • Pommier Y (1993): DNA topoisomerase I and II in cancer chemotherapy: Update and perspectives. Cancer Chemother Pharmacol 32:103–108

    Article  PubMed  CAS  Google Scholar 

  • Potmesil M, Hsiang Y-H, Liu LF, Bank B, Grossberg H, Kirschenbaum S, Forlenzar TJ, Penziner A, Kanganis D, Knowles D, Traganos F, Silber R (1988): Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res 48:3537–3543

    PubMed  CAS  Google Scholar 

  • Prosperi E, Sala E, Negri C, Oliani C, Supino R, Ricotti G BCA, Bottiroli G (1992): Topoisomerase II a and β in human tumor cells grown in vitro and in vivo. Anticancer Res 12:2093–2100

    PubMed  CAS  Google Scholar 

  • Ross W, Rowe T, Glisson B, Yalowich J, Liu LF (1984): Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res 44:5857–5860

    PubMed  CAS  Google Scholar 

  • Rowe TC, Chen GC, Hsiang Y, Liu LF (1986): DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Cancer Res 46:2021–2026

    PubMed  CAS  Google Scholar 

  • Roy C, Brown DL, Little JE, Valentine BK, Walker PR. Sikorska M, LeBlanc J. Chaly N (1992): The topoisomerase II inhibitor teniposide (VM-26) induces apoptosis in unstimulated mature murine lymphocytes. Exp Cell Res 200:416–424

    Article  PubMed  CAS  Google Scholar 

  • Schmoll H (1982): Review of etoposide single-agent activity. Cancer Treat Rev 9:21–30

    Article  PubMed  Google Scholar 

  • Schuetz JD, Matherly LH, Westin EH, Goldman ID (1988): Evidence for a functional defect in the translocation of the methotrexate transport carrier in a methotrexate-resistant murine L1210 leukemia cell line. J Biol Chem 263:9840–9847

    PubMed  CAS  Google Scholar 

  • Sugimoto Y, Tsukahara S, Oh-hara T, Isoe T, Tsuruo T (1990a): Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 50:6925–6930

    CAS  Google Scholar 

  • Sugimoto Y, Tsukahara S, Oh-hara T, Liu LF, Tsuruo T (1990b): Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res 50:7962–7965

    CAS  Google Scholar 

  • Sullivan DM, Glisson BS, Hodges PK, Smallwood-Kentro S, Ross WE (1986): Proliferation dependence of topoisomerase II mediated Drug action. Biochemistry 25:2248–2256

    Article  PubMed  CAS  Google Scholar 

  • Takano H, Kohono K, Ono M, Uchida Y, Kuwano M (1991): Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res 51:3951–3957

    PubMed  CAS  Google Scholar 

  • Takeuchi S, Dobashi K, Fujimoto S, Tanaka K, Suzuki M, Terashima Y, Hasumi K, Akiya K, Negishi Y, Tamaya T, Tanizawa O, Sugawa T, Umesaki N, Sekiba K, Aono T, Nakano H, Noda K, Shiota M, Yakushiji M, Sugiyama T, Hashimoto M, Yajima A, Takamizawa H, Sonoda T, Takeda Y, Tomoda Y, Ohta M, Ozaki M, Hirabayashi K, Hiura M, Hatae M, Nishigaki K, Taguchi T (1991): A late phase II study of CPT-11 in gynecologic cancers. Jpn J Cancer Chemother 18:1681–1689

    CAS  Google Scholar 

  • Tamura H, Kohchi C, Yamada R, Ikeda T, Koiwai O, Patterson E, Keene J, Okada K, Kjeldsen E, Nishikawa K, Andoh T (1990): Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucleic Acids Res 19:69–75

    Article  Google Scholar 

  • Tan KB, Mattem MR, Eng W-K, McCabe FL, Johnson RK (1989): Nonproductive rearrangement of DNA topoisomerase I and II genes: Correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 81:1732–1735

    Article  PubMed  CAS  Google Scholar 

  • Tan KB, Dorman TE, Falls KM, Chung TDY, Mirabelli CK, Crooke ST, Mao J (1992): Topoisomerase IIa and topoisomerase Ilβ genes: Characterization and mapping to human chromosomes 17 and 3, respectively. Cancer Res 52:231–234

    PubMed  CAS  Google Scholar 

  • Tanabe K, Ikegami Y, Ishida R, Andoh T (1991): Inhibition of topoisomerase II by antitumor agents Bis(2,6-dioxopiperazine) derivatives. Cancer Res 51:4903–4908

    PubMed  CAS  Google Scholar 

  • Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF (1984a): Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226:466–468

    Article  CAS  Google Scholar 

  • Tewey KM, Chen GL, Nelson EM, Liu LF (1984b): Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 259:9182–9187

    CAS  Google Scholar 

  • Trask DK, Muller MT (1988): Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D. Proc Natl Acd Sci USA 85:1417–1421

    Article  CAS  Google Scholar 

  • Tsai-Pflugfelder M, Liu LF, Liu AA, Tewey KM, Whang-Peng J, Knutsen T, Huebner K, Kroce CM, Wang JC. (1988): Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21–22. Proc Natl Acad Sci USA 85:7177–7181

    Article  PubMed  CAS  Google Scholar 

  • Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM (1985): The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 229:1390–1393

    Article  PubMed  CAS  Google Scholar 

  • van der Zee AGJ, Hollema H, de Jong S, Boonstra H, Gouw A, Willemse PHB, Zijlstra JG, de Vries EGE (1991): P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumor of the ovary and in malignant tumor of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 51:5915–5920

    PubMed  Google Scholar 

  • Wang JC (1985): DNA topoisomerases. Annu Rev Biochem 54:665–697

    Article  PubMed  CAS  Google Scholar 

  • Wall ME, Wani MC, Cooke CE, Palmer KH, McPhail AT, Slim GA (1966): The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88:3888–3890

    Article  CAS  Google Scholar 

  • Webb CD, Latham MD, Lock RB, Sullivan DM (1991): Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res 51:6543–6549

    PubMed  CAS  Google Scholar 

  • Woessner RD, Chung TDY, Hofman GA, Mattern MR, Mirabelli CK, Drake FH, Johnson RK (1990): Differences between normal and rastransfected NIH-3T3 cells in expression of the 170kD and the 180kD forms of topoisomerase II. Cancer Res 50:2901–2908

    PubMed  CAS  Google Scholar 

  • Woessner RD, Mattem MR, Mirabelli CK, Johnson RK, Drake FH (1991): Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ 2:209–214

    PubMed  CAS  Google Scholar 

  • Wyckoff E, Natalie D, Nolan JM, Lee M, Hsieh T-S (1989): Structure of the Drosophila DNA topoisomerase II gene: Nucleotide sequence and homology. J Mol Biol 205:1–13

    Article  PubMed  CAS  Google Scholar 

  • Wyllie AH, Kerr JFR, Currie AR (1980): Cell death: The significance of apoptosis. Int Rev Cytol 68:251–305

    Article  PubMed  CAS  Google Scholar 

  • Yamashita Y, Kawada S, Nakano H (1990): Induction of mammalian topoisomerase II dependent DNA cleavage by non-intercalative flavonoids, genestein and orobol. Biochem Pharmacol 39:737–744

    Article  PubMed  CAS  Google Scholar 

  • Yamashita Y, Kawada S, Fujii N, Nakano H (1991): Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus. Biochemistry 30:5838–5845

    Article  PubMed  CAS  Google Scholar 

  • Yokoyama M, Himori T, Ujiie S, Saito T (1974): Treatment of malignant neoplasms with Adriamycin. Jpn J Cancer Clin 20:536–544

    Google Scholar 

  • Yoshinari T, Yamada A, Uemura D, Nomura K, Arakawa H, Kojiri K, Yoshida E, Suda H, Okura A (1993): Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110. Cancer Res 53:490–494

    PubMed  CAS  Google Scholar 

  • Zini N, Martelli AM, Sabatelli P, Santi S, Negri C, Ricotti GSBA, Naraldi AM (1992): The 180-kDa isoform of topoisomerase II is located in the nucleolus and belongs to the structural elements of the nuclear remnant. Exp Cell Res 200:460–466

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Teruhiro Utsugi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cynthia E. Herzog
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dominic Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Sunnybrook Health Science Center, University of Toronto, Toronto, Canada, M4N 3M5

    John A. Kellen

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Birkhäuser Boston

About this chapter

Cite this chapter

Utsugi, T., Herzog, C.E., Fan, D. (1995). Topoisomerases in Multidrug Resistance. In: Kellen, J.A. (eds) Alternative Mechanisms of Multidrug Resistance in Cancer. Birkhäuser Boston. https://doi.org/10.1007/978-1-4615-9852-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-9852-7_5

  • Publisher Name: Birkhäuser Boston

  • Print ISBN: 978-1-4615-9854-1

  • Online ISBN: 978-1-4615-9852-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation